Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lactase + ligilactobacillus salivarius DSM 34078
- Development stage
- Preclinical
- Lead developer
- Johnson & Johnson
- Modality
- Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Therapeutic Enzymes → Recombinant Proteins and Enzymes, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
This is a combination product containing **lactase**, an exogenous enzyme that hydrolyzes lactose into glucose and galactose to facilitate lactose digestion, and **Ligilactobacillus salivarius DSM 34078**, a specific strain of probiotic bacteria. The combination is designed to improve **lactose digestion** and reduce gastrointestinal symptoms in individuals with lactose intolerance, potentially providing more prolonged benefit compared to lactase enzyme alone. Lactase acts directly by enzymatic cleavage of dietary lactose, while L. salivarius DSM 34078 is thought to support lactose digestion through probiotic colonization, production of lactase, and modulation of the gut microbiome. This combination targets both the immediate enzymatic breakdown of lactose and the enhancement of gut microbiota's lactase activity[1][3][6].
- Other names
- lactase + lactobacillus salivarius DSM 34078lactase + L. salivarius DSM 34078
Beyond the preview
Go deeper on lactase + ligilactobacillus salivarius DSM 34078.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lactase + ligilactobacillus salivarius DSM 34078.